The ideal reporting of RAS testing in colorectal adenocarcinoma: a pathologists' perspective.

IF 4.4 Q1 PATHOLOGY
PATHOLOGICA Pub Date : 2023-06-14 DOI:10.32074/1591-951X-895
Umberto Malapelle, Valentina Angerilli, Francesco Pepe, Gabriella Fontanini, Sara Lonardi, Mario Scartozzi, Lorenzo Memeo, Gianfranco Pruneri, Antonio Marchetti, Giuseppe Perrone, Matteo Fassan
{"title":"The ideal reporting of <i>RAS</i> testing in colorectal adenocarcinoma: a pathologists' perspective.","authors":"Umberto Malapelle,&nbsp;Valentina Angerilli,&nbsp;Francesco Pepe,&nbsp;Gabriella Fontanini,&nbsp;Sara Lonardi,&nbsp;Mario Scartozzi,&nbsp;Lorenzo Memeo,&nbsp;Gianfranco Pruneri,&nbsp;Antonio Marchetti,&nbsp;Giuseppe Perrone,&nbsp;Matteo Fassan","doi":"10.32074/1591-951X-895","DOIUrl":null,"url":null,"abstract":"<p><p><i>RAS</i> gene mutational status represents an imperative predictive biomarker to be tested in the clinical management of metastatic colorectal adenocarcinoma. Even if it is one of the most studied biomarkers in the era of precision medicine, several pre-analytical and analytical factors may still impasse an adequate reporting of <i>RAS</i> status in clinical practice, with significant therapeutic consequences. Thus, pathologists should be aware on the main topics related to this molecular evaluation: (i) adopt diagnostic limit of detections adequate to avoid the interference of sub-clonal cancer cell populations; (ii) choose the most adequate diagnostic strategy according to the available sample and its qualification for molecular testing; (iii) provide all the information regarding the mutation detected, since many <i>RAS</i> mutation-specific targeted therapeutic approaches are in development and will enter into routine clinical practice. In this review, we give a comprehensive description of the current scenario about <i>RAS</i> gene mutational testing in the clinic focusing on the pathologist's role in patient selection for targeted therapies.</p>","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":" ","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c4/60/pathol-2023-03-137.PMC10462993.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PATHOLOGICA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32074/1591-951X-895","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

RAS gene mutational status represents an imperative predictive biomarker to be tested in the clinical management of metastatic colorectal adenocarcinoma. Even if it is one of the most studied biomarkers in the era of precision medicine, several pre-analytical and analytical factors may still impasse an adequate reporting of RAS status in clinical practice, with significant therapeutic consequences. Thus, pathologists should be aware on the main topics related to this molecular evaluation: (i) adopt diagnostic limit of detections adequate to avoid the interference of sub-clonal cancer cell populations; (ii) choose the most adequate diagnostic strategy according to the available sample and its qualification for molecular testing; (iii) provide all the information regarding the mutation detected, since many RAS mutation-specific targeted therapeutic approaches are in development and will enter into routine clinical practice. In this review, we give a comprehensive description of the current scenario about RAS gene mutational testing in the clinic focusing on the pathologist's role in patient selection for targeted therapies.

Abstract Image

结直肠腺癌RAS检测的理想报告:病理学家的观点。
在转移性结直肠癌的临床治疗中,RAS基因突变状态是一种重要的预测性生物标志物。即使它是精准医学时代研究最多的生物标志物之一,一些分析前和分析因素可能仍然会阻碍临床实践中RAS状态的充分报告,并产生重大的治疗后果。因此,病理学家应该意识到与这种分子评估相关的主要主题:(i)采用足够的诊断检测限制,以避免亚克隆癌细胞群的干扰;(ii)根据可获得的样本及其分子检测资格选择最适当的诊断策略;(iii)提供有关检测到的突变的所有信息,因为许多针对RAS突变的靶向治疗方法正在开发中,并将进入常规临床实践。在这篇综述中,我们对目前临床中RAS基因突变检测的情况进行了全面的描述,重点是病理学家在患者选择靶向治疗中的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
PATHOLOGICA
PATHOLOGICA PATHOLOGY-
CiteScore
5.90
自引率
5.70%
发文量
108
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信